Stage
Preclinical discovery
Area
Small molecule drugs
Status
Ongoing
Patent Status
Not filed yet
Immune aging and chronic inflammation are linked to various age-related diseases, including cardiovascular disease, neurodegeneration, metabolic syndrome, chronic inflammatory conditions, autoimmunity, and cancer. COVID-19 has further highlighted the importance of immune aging as the factor most determinative of death and disability. Additionally, lung infections from other pathogens remain the fourth leading cause of death globally, while tumors can only spread when the immune system fails to control them. Despite the efficacy of immunotherapy, few companies are targeting the hematopoietic stem cells (HSCs) of the bone marrow, which are responsible for producing all blood cells and have the highest replicative capacity of any cell type. Harnessing the immune system is a potent approach in oncology, as evidenced by the immune-oncology (I/O) revolution, which has yielded a Nobel Prize in 2018. However, these methods tend to be "blunt instruments," and few companies are seeking to rejuvenate the entire immune system at the source - the bone marrow and HSCs. HSCs, when rejuvenated in the lab, can extend the healthy lifespan of lab animals up to 30%.
ImmuneAGE Bio is a biotech startup aiming to rejuvenate the immune system through its lead compound IA101, which targets HSCs. The company plans to strengthen the IP of IA101 by developing new analogs and identifying the molecular target.
ImmuneAGE's lead program, IA101, is a non-toxic small molecule that can rejuvenate aged HSCs and aged animal immune function with higher efficacy than any molecule previously published. A less potent natural product analog of IA101 has shown efficacy and safety in multiple human clinical trials, which has de-risked clinical development. The company plans to develop new IA101 analogs to enhance potency and drug-likeness and to identify the molecular target to move towards IND. With ImmuneAGE's unique screening platform, they aim to quickly iterate new candidates to select a final pre-clinical candidate. The company will file intellectual property around the optimized IA101 derivatives discovered from the funding of this project.
Timeline
Pre-Clinical Studies
Required Funding: $500k-1M
Status: Ongoing
Duration: 12-14 months
The proposal for ImmuneAGE Bio has been evaluated by a team of experts, receiving an average score of 4/5. The proposal highlights that ImmuneAGE is the first LongBio company focusing solely on immune aging drug discovery. The lead asset, IA101, has already demonstrated promising in-vivo proof of concept data and outperformed all other HSC immune compounds in the literature. The founder is a prominent entrepreneur in the longevity space, and the team has considerable experience in drug development, immunology, venture capital, and pharma/biotech. The company also has a prestigious investor base at an early stage.
However, there are some risks associated with the proposal. Immune rejuvenation is uncharted territory, and the company needs to prioritize its clinical strategy to focus on the right indication. The target of IA101 is unknown, although the company has plans to identify it. Additionally, life extension in mice may not necessarily translate to humans, as with any other candidate longevity intervention. Finally, the company is still in the early stages and faces financing risks if market conditions weaken, although their pre-seed round was heavily oversubscribed and raised quickly in less than a month.
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.